Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immune drug targets Hard-to-Treat cancers in early trial

NCT ID NCT07156136

Recruiting now Disease control Sponsor: Immunocore Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called IMC-P115C in people with advanced cancers that have a specific protein (PRAME) and a certain immune type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The study will check safety and whether the drug works alone or with standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IMC-P115C (an immune therapy that targets cancer cells with a protein called PRAME)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced cancers that have the PRAME protein.
What could go wrong
This is a very early Phase 1 trial with only 140 participants, so it is not yet known if the drug is safe or effective. There may be side effects, and the treatment may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER HLA-A*02:01-POSITIVE PRAME POSITIVE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Cancer Research South Australia (CRSA)

    RECRUITING

    Adelaide, 5000, Australia

  • Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)

    RECRUITING

    Toulouse, 31059, France

  • Fondazione IRCCS - Istituto Nazionale dei Tumori

    RECRUITING

    Milan, 20133, Italy

  • Hospital Universitari Vall d Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario Ramon y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals

    RECRUITING

    Barcelona, 08908, Spain

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Istituto Europeo di Oncologia

    RECRUITING

    Milan, 20141, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"

    RECRUITING

    Naples, 80131, Italy

  • Linear Clinical Research ltd.

    RECRUITING

    Nedlands, 06009, Australia

  • Melanoma Institute Australia

    RECRUITING

    Wollstonecraft, 2065, Australia

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz

    RECRUITING

    Madrid, 28040, Spain

  • UNICANCER - Centre Leon-Berard (CLB)

    RECRUITING

    Lyon, 69008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.